NEW YORK -(Dow Jones)- A Mylan Laboratories Inc. spokeswoman Monday
confirmed a report that the Federal Trade Commission has subpoenaed the
company for information on its drug pricing.
   Monday's edition of USA Today reported that the FTC has been looking
into the company's pricing practices.
   Vice President Patricia Sunseri confirmed that in May, the FTC asked
Mylan for information on the company's pricing policy. Mylan (MYL)
provided the requested information, she said.
   Then, about three weeks ago, the FTC sent a subpoena asking for
information on its Italian raw materials provider Profarmica, Sunseri
said.
   Mylan currently has a contract with Profarmica for three ingredients,
Sunseri said - the generic tranquilizers lorazepam and clorazepate, and
methyclothiazide, a diuretic.
   Sunseri said Mylan was losing money or "just trading dollars" on 41
out of its total 97 products."
   The company raised prices on 14 of those products as part of an
effort to see if it could make a profit on the products before dropping
them. The products are now profitable for the company, she said.
   The FTC's investigation follows complaints by competitors that Mylan
increased prices on generic drugs after forming an exclusive arrangement
with a major supplier that cut off other generic drug companies.
   Last week, Mylan claimed that it was forced to raise prices because
of unfair tactics on the part of brand-name drug manufacturers to keep
generic competitors at bay.